Abstract:Background Optimum management strategies for patients with advanced non-small-cell lung cancer (NSCLC) with acquired resistance to EGFR tyrosine-kinase inhibitors are undefined. We aimed to assess the efficacy and safety of continuing gefitinib combined with chemotherapy versus chemotherapy alone in patients with EGFR-mutation-positive advanced NSCLC with acquired resistance to first-line gefitinib.Methods The randomised, phase 3, multicentre IMPRESS study was done in 71 centres in 11 countries in Europe and the Asia-Pacific region. Eligible patients were aged at least 18 years with histologically confirmed, chemotherapynaive, stage IIIB-IV EGFR-mutation-positive advanced NSCLC with previous disease control with first-line gefitinib and recent disease progression (Response Evaluation Criteria in Solid Tumors version 1.1). Participants were randomly assigned (1: 1) by central block randomisation to oral gefitinib 250 mg or placebo once daily in tablet form; randomisation did not include stratification factors. All patients also received the platinum-based doublet chemotherapy cisplatin 75 mg/m(2) plus pemetrexed 500 mg/m(2) on the first day of each cycle. After completion of a maximum of six chemotherapy cycles, patients continued their randomly assigned treatment until disease progression or another discontinuation criterion was met. All study investigators and participants were masked to treatment allocation. The primary endpoint was progression-free survival in the intention-to-treat population. Safety was assessed in patients who received at least one dose of study treatment. The study has completed enrolment, but patients are still in follow-up for overall survival. This trial is registered with ClinicalTrials.gov, number NCT01544179.Findings Between March 29, 2012, and Dec 20, 2013, 265 patients were randomly assigned: 133 to the gefitinib group and 132 to the placebo group. At the time of data cutoff (May 5, 2014), 98 (74%) patients had disease progression in the gefitinib group compared with 107 (81%) in the placebo group (hazard ratio 0 . 86, 95% CI 0 . 65-1 . 13; p=0 . 27; median progression-free survival 5 . 4 months in both groups [95% CI 4 . 5-5 . 7 in the gefitinib group and 4 . 6-5 . 5 in the placebo group]). The most common adverse events of any grade were nausea (85 [64%] of 132 patients in the gefitinib group and 81 [61%] of 132 patients in the placebo group) and decreased appetite (65 [49%] and 45 [34%]). The most common adverse events of grade 3 or worse were anaemia (11 [8%] of 132 patients in the gefitinib group and five [4%] of 132 patients in the placebo group) and neutropenia (nine [7%] and seven [5%]). 37 (28%) of 132 patients in the gefitinib group and 28 (21%) of 132 patients in the placebo group reported serious adverse events.Interpretation Continuation of gefitinib after radiological disease progression on first-line gefitinib did not prolong progression-free survival in patients who received platinum-based doublet chemotherapy as subsequent line of treatment. Platinum-based doublet chemotherapy remains the standard of care in this setting.

Retreatment after the Failure of Initial Epidermal Growth Factor Receptor Inhibitor in Non-Small Cell Lung Cancer

Epidermal Growth Factor Receptor‐tyrosine Kinase Inhibitor Therapy is Effective As First‐line Treatment of Advanced Non‐small‐cell Lung Cancer with Mutated EGFR: A Meta‐analysis from Six Phase III Randomized Controlled Trials

Progress on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor for Treatment of Advanced Non-Small Cell Lung Cancer

Continuing EGFR-TKI in Combination with Super-Selected Arterial Infusion Chemotherapy Beyond RECIST PD for Patients with Advanced EGFR Positive Mutation Non-Small Cell Lung Cancer.

Gefitinib As Third-Line Re-Challenge Treatment in Advanced NSCLC Patients with EGFR Activating Mutation Who Benefited from First-Line Gefitinib Treatment Followed by Second-Line Chemotherapy.

Clinical Efficacy of Erlotinib in Patients Previously Treated for Advanced Non‐small Cell Lung Cancer

Continuation of gefitinib plus chemotherapy prolongs progression-free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations.

Readministration of EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients after Initial Failure, What Affects Its Efficacy?

Remarkable effect of gefitinib retreatment in a patient with nonsmall cell lung cancer who had a complete response to initial gefitinib

Gefitinib or Erlotinib Vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

Gefitinib Plus Chemotherapy Versus Placebo Plus Chemotherapy in Egfr-Mutation- Positive Non-Small-Cell Lung Cancer after Progression on First-Line Gefitinib (impress): A Phase 3 Randomised Trial

Mefatinib As First-Line Treatment of EGFR Sensitizing Mutation-Positive Non-Small-cell Lung Cancer: A Phase III Efficacy and Biomarker Study.

P3.02b-104 Rebiopsy for Patients with Non-Small-Cell Lung Cancer after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Failure

Rechallenge with EGFR-TKI after failure of immunotherapy is considered an effective treatment for advanced lung adenocarcinoma patients with EGFR exon 19 deletion: a case report

Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer

Efficacy and Safety of Gefitinib As Third-line Treatment in NSCLC Patients with Activating EGFR Mutations Treated with First-line Gefitinib Followed by Second-line Chemotherapy

Initial Progression-Free Survival after Non-First Line TKIs Therapy Potentially Guides Immediate Treatment after Its Failure in Advanced Non-Small Cell Lung Cancer.

Application of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor As the First-line Therapy in Patients with Advanced Non-small Cell Lung Cancer

Erlotinib As A Salvage Treatment for Patients with Advanced Non-Small Cell Lung Cancer after Failure of Gefitinib Treatment

Erlotinib as a salvage treatment after gefitinib failure for advanced non-small-cell lung cancer patients with brain metastasis: A successful case report and review

The Efficacy Of Chemotherapy In The Advanced Nsclc Patients Who Failed With The Treatment Of Egfr-Tki